

Japan commercialises world's first test for early-stage pancreatic cancer

17 November 2022 | News

“N-NOSE plus Pancreas” may greatly contribute to early detection and early treatment of pancreatic cancer

Hirotsu Bio Science Inc. has announced the commercialisation of "N-NOSE plus Pancreas," the first next-generation "cancer type specific test" for the "N-NOSE".

"N-NOSE plus Pancreas" is the world's first test that can detect early-stage pancreatic cancer. Through the "N-NOSE plus Pancreas", Hirotsu aims to achieve early detection of as many cases of pancreatic cancer as possible and contribute to improving pancreatic cancer treatment results.

Hirotsu has been conducting research and development of a "cancer-specific test" as a next-generation test for the "N-NOSE" primary cancer screening test that was launched in January 2020, and has been putting all efforts into research and development in order to commercialise a specific test for pancreatic cancer, which is particularly difficult to detect in its early stage.

In November 2021, the company succeeded in creating a "special nematode" that specifically reacts to the smell of pancreatic cancer by genetically modifying *C. elegans* nematodes. Subsequent research confirmed that this special nematode is capable of detecting early-stage pancreatic cancer, and after completing verification tests at a testing center, the company has now commercialised the "N-NOSE plus Pancreas".